Innate Pharma SA
IPHANasdaqHealthcare · Biological Products, (No Diagnostic Substances) · I0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
FDA-approved drugs
openFDA · most recent- LUMOXITISep 13, 2018
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2025-06IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
- Phase 1Recruitingreadout ~2028-04Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Novo Nordisk A SPassive (13G)Apr 10, 2026
- Astrazeneca PlcActivist (13D)Feb 6, 2026
- Bpifrance Participations SaActivist (13D)May 7, 2025
- SanofiPassive (13G)Apr 29, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 245,729 | 1.0 | +171.5% |
| Apr 30, 2026 | 90,515 | 3.9 | +41.0% |
| Apr 15, 2026 | 64,220 | 2.3 | -9.9% |
| Mar 31, 2026 | 71,264 | 3.1 | -6.5% |
| Mar 13, 2026 | 76,183 | 4.4 | -23.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.